First-line Data for ROS1-Altered Advanced NSCLC
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Released: September 05, 2024

Expiration: September 04, 2025

Activity

Progress
1
Course Completed

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

  • Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
  • Long-term safety observations for crizotinib and entrectinib
  • CNS activity of entrectinib and repotrectinib in patients with brain metastases
  • Repotrectinib activity in ROS1-TKI resistance mutations